Association of Bridging Therapy Utilization with Clinical Outcomes in Patients Receiving Chimeric Antigen Receptor (CAR) T-Cell Therapy
Association of Bridging Therapy Utilization with Clinical Outcomes in Patients Receiving Chimeric Antigen Receptor (CAR) T-Cell Therapy
- # Chimeric Antigen Receptor
- # Chimeric Antigen Receptor T-cell Therapy
- # Immune Effector Cell-associated Neurotoxicity Syndrome
- # Bridging Therapy
- # Travel Support
- # Complete Response
- # Rates Of Cytokine Release Syndrome
- # Receive Bridging Therapy
- # Patients Receiving Chimeric Antigen Receptor T-cell Therapy
- # Receiving Chimeric Antigen Receptor T-cell Therapy
- Research Article
- 10.1182/blood-2025-7256
- Nov 3, 2025
- Blood
Glofitamab based combined therapy as bridging therapy before stem cell transplants and CAR-T therapy in large B-cell lymphoma.
- Abstract
6
- 10.1182/blood-2019-131499
- Nov 13, 2019
- Blood
Radiation Therapy Can be an Effective Bridging Strategy Prior to Axicabtagene Ciloleucel Therapy for Relapsed/Refractory Large B-Cell Lymphoma
- Abstract
- 10.1016/s2666-6367(21)00242-6
- Jan 31, 2021
- Transplantation and Cellular Therapy
216 - The Impact of Bridging Therapy Prior to CAR-T Cell Therapy on Clinical Outcomes of Patients with Relapsed Refractory Large B-Cell Lymphoma
- Abstract
1
- 10.1182/blood-2020-141231
- Nov 5, 2020
- Blood
The Impact of Bridging Therapy Prior to CAR-T Cell Therapy on Clinical Outcomes of Patients with Relapsed Refractory Large B-Cell Lymphoma
- Research Article
4
- 10.4037/aacnacc2022936
- Dec 15, 2022
- AACN Advanced Critical Care
Chimeric Antigen Receptor T Cells: Toxicity and Management Considerations
- Research Article
44
- 10.1016/s1470-2045(21)00353-3
- Jul 1, 2021
- The Lancet Oncology
CAR T-cell therapy for solid tumours
- Abstract
2
- 10.1182/blood-2020-136756
- Nov 5, 2020
- Blood
Gut Bacterial Diversity Associates with Efficacy of Anti-CD19 CAR T-Cell Therapy in Patients with Large B-Cell Lymphoma
- Abstract
38
- 10.1182/blood-2023-181857
- Nov 2, 2023
- Blood
BMS-986393 (CC-95266), a G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from a Phase 1 Study
- Research Article
- 10.1182/blood-2025-3706
- Nov 3, 2025
- Blood
Impact of TP53 mutations on survival outcomes in the CAR-t era of large b-cell lymphoma
- Research Article
- 10.1182/blood-2024-201809
- Nov 5, 2024
- Blood
Autoimmune Outcomes in Patients with Concurrent Autoimmune Disease Receiving CD19 CAR T-Cell Therapy for Lymphoma
- Abstract
8
- 10.1182/blood-2022-162594
- Nov 15, 2022
- Blood
CAR T-Cell Therapy Remain Effective in Patients with Relapse/Refractory B-Cell Non-Hodgkin Lymphoma after Bispecific Antibodies Exposure: Results of a Lysa Study Based on the Descar-T Registry
- Research Article
18
- 10.1111/bjh.18339
- Jun 28, 2022
- British Journal of Haematology
Feasibility of outpatient administration of axicabtagene ciloleucel and brexucabtagene autoleucel using telemedicine tools: The Vanderbilt experience.
- Research Article
2
- 10.1182/blood-2024-202243
- Nov 5, 2024
- Blood
Demographic Characteristics, Incidence and Outcomes of Cytokine Release Syndrome and Immune Effector Cell-Associated Neurotoxicity Syndrome in Patients Undergoing CAR T-Cell Therapy: An Analysis of the National Inpatient Sample (NIS) - 2021
- Research Article
- 10.1182/blood-2025-3722
- Nov 3, 2025
- Blood
Cytomegalovirus (CMV) reactivation negatively impacts survival after CAR T-cell therapy in lymphoma patients: Results from the CART-SIE study
- Abstract
- 10.1182/blood-2022-162411
- Nov 15, 2022
- Blood
Efficacy and Safety of Intravenous Chimeric Antigen Receptor T-Cell Therapy in Adults with Primary Central Nervous System Lymphoma: A Systematic Review and Meta-Analysis
- Ask R Discovery
- Chat PDF
AI summaries and top papers from 250M+ research sources.